DMT, a hallucinogenic drug — to extend survival in clinical death

Help fund crucial, pivotal studies and experiments which can possibly save lives in the future

Debrecen, Hungary – June 9, 2015 – When a person’s heart stops beating, they enter clinical death. This means the person has an estimated five minutes left until terminal death. Clinical death is not final. It can be reversed, thanks to the continuously evolving techniques of cardiopulmonary resuscitation. Yet, these moments are pivotal as it is the difference between life or death. After these five minutes have passed, second after second the dying person exponentially loses the chance of recovering life. However, there is data suggesting that dimethyltryptamine (DMT), a so called hallucinogenic drug, can extend this important period of time.

This leaves a group of basic and clinical researchers, who follow the line of investigation started by Stephen Szara’s groundbreaking clinical studies with DMT, needing funds to develop their study. So, they started an IndieGoGo campaign, with a goal of raising $30,000 by August 1, 2015. The funds received would go to crucial experiments, research materials, and oxygen chamber setup. The planned pivotal invitro (“test tube”) study can lead to clinical studies in humans with the goal of improved reversal of clinical death and ultimately may result in saving numerous lives.

To help fund these potentially lifesaving studies, please visit the IndieGoGo campaign or click here. Backers can choose from many attractive rewards as a “thank you” for their donations.

For anyone that is not familiar with how IndieGoGo works, it allows the company to keep any contributions made. If the campaign does not reach the goal then the project can keep what they’ve raised and move forward. So, help this group of researches receive any financial support possible. Remember that any amount given counts. Help spread the word about this potentially life saving study by sharing this on Facebook, Twitter, and other social networks.

For further information please feel free contacting the Principal Investigator:

Media Contact
Company Name: University of Debrecen
Contact Person: Ede Frecska, M.D., Ph.D.
Phone: +36 (30) 402-6402
Country: Hungary